An intranasal influenza vaccine for the prevention of influenza in healthy children was cost-effective.

@article{Schwartz2002AnII,
  title={An intranasal influenza vaccine for the prevention of influenza in healthy children was cost-effective.},
  author={Ben Schwartz},
  journal={ACP journal club},
  year={2002},
  volume={136 2},
  pages={75}
}
Main cost and outcome measures Cost per febrile influenza-like illness (ILI) day avoided. A break-even analysis was also done to calculate the vaccine plus administration cost below which its use would be cost saving. Per child cost-effectiveness analyses were done separately for an individual based and group based vaccination delivery scenario from the societal and third-party payer perspectives. Costs were assessed in US dollars and were discounted at a rate of 3% in year 2.